Clinical trial TCD17710
A First-in-human, open-label Phase 1/2 study to investigate safety and efficacy of SAR445514, an NK-cell engager (NKCE) targeting B-cell maturation antigen (BCMA) in monotherapy in participants with relapsed/refractory multiple myeloma (RRMM) and in relapsed/refractory light[1]chain amyloidosis (RRLCA)
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial closed |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1/2 |
| Academic trial | Non |
| Sponsor | Sanofi-Aventis |
| EudraCT Identifier | 2022-502057-33-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05839626 |
| Inclusion criteria | RRMM: at least 2 prior lines of therapy with at least 2 consecutive cycles of a second or third generation immunomodulator (lenalidomide or pomalidomide), steroid (dexamethasone), proteasome inhibitor (bortezomib, carfilzoib, ixazomib) and anti-CD38 MoAb |
| Last update |